Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182573 | 0.92 | CA12 (0.34) | KCNK3KCNK9PDE2ACYP1A2CYP2C9 | |
| SCHEMBL621959 | 0.88 | EPHX2 (0.33) | PDE2AEPHX2 | |
| SCHEMBL8674 | 0.81 | CA2 (0.46) | CYP1A2CYP2C9CYP2C19CA12CA1 | |
| SCHEMBL16959238 | 0.80 | L3MBTL1 (0.35) | CYP1A2CYP2C9CYP2C19EPHX2 | |
| SCHEMBL1065737 | 0.80 | PDE2A (0.33) | PDE2AEPHX2 | |
| SCHEMBL2138768 | 0.79 | CA2 (0.43) | CYP1A2CYP2C9CYP2C19CA12CA1 | |
| SCHEMBL27494520 | 0.79 | CA2 (0.43) | CYP1A2CYP2C9CYP2C19CA12CA1 | |
| SCHEMBL28251730 | 0.79 | CA2 (0.43) | CYP1A2CYP2C9CYP2C19CA12CA1 | |
| SCHEMBL1068712 | 0.78 | SCN5A (0.33) | PDE2AEPHX2 | |
| SCHEMBL1068429 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777121-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-29 | — | — | CN | claimed |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | claimed |
| EP-3774732-A2 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2021-02-17 | — | — | EP | claimed |
| WO-2019193516-A2 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | WO | claimed |
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | US | claimed |
| EP-3529245-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2019-08-28 | — | — | EP | claimed |
| WO-2018081167-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2018-05-03 | — | — | WO | claimed |
| US-11970486-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-30 | — | — | US | disclosed |
| US-20240124435-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-18 | — | — | US | disclosed |
| CN-117777121-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| CN-110099898-B | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | disclosed |
| EP-0154887-B1 | NEW 2,5-DIARYL TETRAHYDROTHIOPHENES AND ANALOGS THEREOF AS PAF-ANTAGONISTS | MERCK & CO. INC. (US) | 1989-01-25 | — | — | EP | disclosed |
| EP-0257921-A2 | New 1,3-diaryl cyclopentanes and derivatives thereof as paf antagonists | MERCK & CO. INC. (US) | 1988-03-02 | — | — | EP | disclosed |
| EP-0199324-A2 | New 2,5-diaryl tetryhydrofurans and analogs thereof as paf antagonists | MERCK & CO. INC. (US) | 1986-10-29 | — | — | EP | disclosed |
| US-4595693-A | Method of use of 2,5-diaryl tetrahydrofurans and analogs thereof as PAF-antagonists | MERCK & CO., INC. (US) | 1986-06-17 | — | — | US | disclosed |
| EP-0154887-A1 | New 2,5-diaryl tetrahydrothiophenes and analogs thereof as paf-antagonists | MERCK & CO. INC. (US) | 1985-09-18 | — | — | EP | disclosed |
| US-4539332-A | PLATELET ACTIVATION FACTOR | MERCK & CO., INC. (US) | 1985-09-03 | — | — | US | disclosed |
| EP-0144804-A2 | New 2,5-diaryl tetrahydrofurans and analogs thereof as paf-antagonists | MERCK & CO. INC. (US) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | KCNK3 2866/4885KCNK9 2769/4885PDE2A 3259/4885 |
| US-20240124435-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | KCNK3 1621/4885KCNK9 2133/4885PDE2A 453/4885 |
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | KCNK3 1621/4885KCNK9 2133/4885PDE2A 453/4885 |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | KCNK3 2866/4885KCNK9 2769/4885PDE2A 3259/4885 |
| US-11970486-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | KCNK3 1621/4885KCNK9 2133/4885PDE2A 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.